Literature DB >> 15894666

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.

Gary M Clifford1, Rashida K Rana, Silvia Franceschi, Jennifer S Smith, Gerald Gough, Jeanne M Pimenta.   

Abstract

Low-grade squamous intraepithelial lesions (LSIL) associated with certain human papillomavirus (HPV) genotypes may preferentially progress to cervical cancer. HPV genotyping may thus have the potential to improve the effectiveness of screening programs and to reduce overtreatment. LSIL cases (n = 8,308) from 55 published studies were included in a meta-analysis. HPV genotype distribution was assessed by geographic region and in comparison with published data on cervical squamous cell carcinoma (SCC). HPV detection in LSIL was 80% in North America but less than 70% in other regions, most likely reflecting regional differences in LSIL diagnosis. Among 5,910 HPV-positive LSILs, HPV16 was the most common genotype (26.3%) followed by HPV31 (11.5%), HPV51 (10.6%), and HPV53 (10.2%). HPV-positive LSILs from Africa were 2-fold less likely to be infected with HPV16 than those in Europe, and HPV-positive LSILs from North America were more likely to be infected with HPV18 than those from Europe or South/Central America. Interpretation for rarer genotypes was hampered by variation in HPV testing methodology. SCC/LSIL prevalence ratios indicated that HPV16 was 2-fold and HPV18 was 1.5-fold more common in SCC than in HPV-positive LSIL, thus appearing more likely to progress than other high-risk genotypes (SCC/LSIL prevalence ratios between 0.05 and 0.85). HPV53 and HPV66 showed SCC/LSIL ratios of 0.02 and 0.01, respectively. HPV genotype distribution in LSIL differs from that in cervical cancer, highlighting the importance of HPV genotype in the risk of progression from LSIL to malignancy. Some regional differences in the relative importance of HPV genotypes in LSIL were noted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894666     DOI: 10.1158/1055-9965.EPI-04-0812

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  133 in total

1.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

Review 2.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

3.  Do you approve of spending $300 million on HPV vaccination?: yes.

Authors:  Marc Steben
Journal:  Can Fam Physician       Date:  2008-02       Impact factor: 3.275

4.  Prevalence of high-risk HPV types and abnormal cervical cytology in American Indian/Alaska Native women, 2003-2005.

Authors:  Grace A Alfonsi; S Deblina Datta; Theresa Mickiewicz; Laura A Koutsky; Khalil Ghanem; Michael Hagensee; Peter Kerndt; Katherine Hsu; Hillard Weinstock; Judith C Shlay
Journal:  Public Health Rep       Date:  2011 May-Jun       Impact factor: 2.792

5.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

Review 6.  Human papillomavirus in Ethiopia.

Authors:  Awoke Derbie; Daniel Mekonnen; Gizachew Yismaw; Fantahun Biadglegne; Xaveer Van Ostade; Tamrat Abebe
Journal:  Virusdisease       Date:  2019-04-20

Review 7.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Human papillomavirus types distribution in eastern Sicilian females with cervical lesions. A correlation with colposcopic and histological findings.

Authors:  Maria Le Donne; Giuseppe Giuffrè; Carmela Caruso; Piero Antonio Nicotina; Angela Alibrandi; Rosalba Scalisi; Angela Simone; Benito Chiofalo; Onofrio Triolo
Journal:  Pathol Oncol Res       Date:  2013-02-19       Impact factor: 3.201

9.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

10.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline.

Authors:  Mark Schiffman; Gary Clifford; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2009-06-01       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.